tiprankstipranks

Medtronic announces outcomes from two studies in AFib patients

Medtronic (MDT) announced positive clinical outcomes from two studies in atrial fibrillation, AFib, patients treated with the Affera family of technologies, including the next-generation Sphere-360 single-shot pulsed field ablation catheter and the groundbreaking Sphere-9 combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal. The company said; One-year clinical trial data for the next-generation, investigational, Sphere-360 single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib; Dual-energy, focal Sphere-9 catheter demonstrates efficacy for linear ablation in persistent AFib; Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue